Cream for atopic eczema launched
A cream containing 1 per cent pimecrolimus (Elidel) for the treatment
of eczema has been launched by Novartis (see p563). Pimecrolimus works
by inhibiting the activation of T-cells and the release of inflammatory
cytokines from cells within the skin.
The product is indicated for use in patients aged two years and over
with mild to moderate atopic dermatitis (eczema) for both short-term treatment
of signs and symptoms, and intermittent long-term treatment for the prevention
of flare-ups. The company suggests that the cream should be used at the
first signs of skin worsening, such as redness and itching.
Because of the low level of systemic absorption of pimecrolimus, there
is no restriction in either the total daily dose applied, in the extent
of the body surface area treated or in the duration of treatment. However,
if no improvement occurs after six weeks, or in the case of disease exacerbation,
the cream should be stopped and further therapeutic options considered.
|
